SUPN - Supernus Pharmaceuticals GAAP EPS of $0.03 misses by $0.33 revenue of $177.35M beats by $4.87M

• Supernus Pharmaceuticals press release ( NASDAQ: SUPN ): Q3 GAAP EPS of $0.03 misses by $0.33 .
• Revenue of $177.35M (+19.4% Y/Y) beats by $4.87M .
• Third quarter 2022 Qelbree net product sales of $18.3 million increased 65% compared to second quarter of 2022;
• At September 30, 2022, the Company’s cash, cash equivalents, current and long-term marketable securities are approximately $523.7 million, compared to $458.8 million as of December 31, 2021. This increase was primarily due to cash generated from operations.
• Raised Outlook: Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million to $40 million previously
• Increasing full year 2022 total revenues guidance to $650 million to $680 million, from $640 million to $680 million previously

For further details see: